Evaluation of the effects of noniodinized and iodinized ionic contrast media and gadoteric acid in acute necrotizing pancreatitis: experimental study in rabbits.
OBJECTIVE
To evaluate the effects of iodine contrast media and gadoteric acid in acute necrotizing pancreatitis.


METHODS
Fifty rabbits were distributed in 5 groups: 10 rabbits were assigned in the control group (group 5) and 40 rabbits were assigned in the pancreatitis group, wherein acute necrotizing pancreatitis was induced through retrograde injection of 5% sodium taurocholate (1 mL/kg weight) in the main pancreatic duct. After 3 hours, they were randomized to receive endovenous iodinized nonionic contrast medium (group 1), iodinized ionic contrast medium (group 2), gadoteric acid (group 3), and physiological serum at 0.9% (group 4). Six hours after induction of pancreatitis, these animals were reoperated. During surgery, pancreatic tissue flow through laser Doppler, hematometric values, biochemistry, and histopathology analysis by hematoxylin and eosin were done. Statistical analysis using Kruskal-Wallis, Fisher-Freeman-Halton, and parametric t tests was performed.


RESULTS
There was statistical significance when comparing tissue flow before and after induction of pancreatitis (P < 0.0001). Ionic and nonionic contrast media and gadoteric acid did not increase the grade of pancreatic necrosis (P > 0.05).


CONCLUSIONS
Ionic and nonionic contrast media and gadoteric acid did not produce adverse effects in the present model of acute necrotizing pancreatitis.
Apodaca-Torrez
Franz R
FR
Department of Surgery, Discipline of Gastric Surgery, Federal University of São Paulo, São Paulo, Brazil. apodaca@uol.com.br
Goldenberg
Alberto
A
Lobo
Edson J
EJ
Farah
José F M
JF
Triviño
Tarcisio
T
Montero
Edna Frasson S
EF
Schraibman
Vladimir
V
Benvenuto
Ricardo B
RB
Artigiani Neto
Ricardo
R
D000818:Animals; D003287:Contrast Media / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D004195:Disease Models, Animal; D006571:Heterocyclic Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D007275:Injections, Intravenous; D007472:Iohexol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D007482:Iothalamate Meglumine / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D017078:Laser-Doppler Flowmetry; D009336:Necrosis; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D009994:Osmolar Concentration; D010179:Pancreas / Q000098:blood supply / Q000187:drug effects* / Q000473:pathology; D019283:Pancreatitis, Acute Necrotizing / Q000139:chemically induced / Q000473:pathology* / Q000503:physiopathology; D011817:Rabbits; D012039:Regional Blood Flow / Q000187:drug effects; D013656:Taurocholic Acid; D013997:Time Factors
D003287:Contrast Media; D006571:Heterocyclic Compounds; D009942:Organometallic Compounds; C093233:iobitridol; D007472:Iohexol; C001694:meglumine ioxithalamate; D013656:Taurocholic Acid; C050823:gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate; D007482:Iothalamate Meglumine